SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

BAY 1135626

Cat. No.:	HY-147281
CAS No.:	1404071-37-9
Molecular Formula:	$C_{55}H_{86}N_{10}O_{11}$
Molecular Weight:	1063.33
Target:	Drug-Linker Conjugates for ADC
Pathway:	Antibody-drug Conjugate/ADC Related
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (94.04 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	0.9404 mL	4.7022 mL	9.4044 mL
	5 mM	0.1881 mL	0.9404 mL	1.8809 mL
	10 mM	0.0940 mL	0.4702 mL	0.9404 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 3.5 mg/mL (3.29 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 3.5 mg/mL (3.29 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 3.5 mg/mL (3.29 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

BAY 1135626 is used to synthesize BAY 1129980, and use to anti-tumor research. BAY 1129980 is a Auristatin-based anti-C4.4A (LYPD3) antibody–agent conjugate (ADC), is used to non–small cell lung cancer (NSCLC) research[1].

In Vitro

C4.4A (LYPD3) is a protein expressed in non-small cell lung cancer (NSCLC), with scarcely expressing in normal tissues[1].
BAY 1135626 can be synthesized into BAY 1129980 (C4.4A-ADC), shows a strong anti-proliferative effect on C4.4A expressing cell lines[1].
BAY 1129980 (0.001-100 nM; 72 h) inhibits the proliferation of A549 lung cancer cell lines transfected with C4.4A[1].
BAY 1129980 (0.001-100 nM; 72 h) exhibits high and selective efficacy on hC4.4A:A549 cells in vitro[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay[1]

Cell Line:	hC4.4A:A549 lung cancer cells
Concentration:	0.001-100 nM
Incubation Time:	72 hours
Result:	High potency at subnanomolar range with an IC_{50} value of 0.05 nM. Resulted remarkable selectivity on hC4.4A:A549 with over 1,000-fold compared with mock:A549 cells.

Cell Viability Assay[1]

Cell Line:	NCI-H292, FaDu, NCI-H322, SCaBER, SCC-4
Concentration:	0.001-100 nM
Incubation Time:	72 hours
Result:	Inhibited cancer cell growth in a dose-dependent manner.

In Vivo

BAY 1129980 (1.9-7.5 mg/kg; i.v.; 20 d) inhibits tumor growth in vivo in mouse[1].
BAY 1129980 with a repeated dosing (15 mg/kg; i.v.; 21 d for 1st cycle and 57 d for 2nd cycle) is well tolerated without changing the sensitivity to the treatment[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C4.4A-positive NCI-H292 NSCLC xenograft mouse model[1]
Dosage:	1.9, 3.75, 7.5 mg/kg
Administration:	Intravenous injection; 20 days
Result:	Halted tumor growth on day 20 dose dependently, as the monotherapy treatment, with a minimum effective dose (MED) of 1.9 mg/kg.

Animal Model:	C4.4A-positive NCI-H292 NSCLC xenograft mouse model[1]
Dosage:	15 mg/kg
Administration:	Intravenous injection; 21 days for the first cycle teament, 57 days for the second cycle treatment
Result:	Reduced tumor volume with a marked delay of tumor growth. Demonstrated well tolerance, still left regrown tumors sensitive to treatment.

REFERENCES

[1]. Willuda J, et al. Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer. Mol Cancer Ther. 2017 May. 16(5):893-904.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA